ATAI:NASDAQ
AtaiBeckley Inc
$4.53
arrow_downward
-5.82%(-0.28) 1 日
$4.53
0.00% (0.00)
bedtime時間外取引
終了: 6月3日, 16:00:01 GMT-4 · USD
search
すべての記号
1 日
5 日
1 か月
6 か月
年初来
1 年
5 年
最大
| 記号 | 価格 | 変化 | 変化率 |
|---|
insights_autoATAI の上位の分析情報を生成しています...
始値
$4.78
高値
$4.78
安値
$4.46
時価総額
16.77億
平均出来高
517.82万
取引量
410.20万
52 週高値
$6.72
52 週安値
$2.00
EPS
-$2.23
ベータ版
1.60
発行済株式数
3.68億
従業員数
99
始値
$4.78
高値
$4.78
安値
$4.46
時価総額
16.77億
平均出来高
517.82万
取引量
410.20万
52 週高値
$6.72
52 週安値
$2.00
EPS
-$2.23
ベータ版
1.60
発行済株式数
3.68億
従業員数
99
ニュース記事
ウェブの情報から
TradingView
·
2 時間前
ATAI: BPL-003 phase III for depression begins, with VLS-01 phase IIb results due Q4 2024
Stock Titan
·
8 時間前
AtaiBeckley (NASDAQ: ATAI) to present BPL-003 Phase 3 updates
The Legal Advocate
·
1 週間前
AtaiBeckley Inc. (ATAI) Surges 5.87%: Testing Key Resistance Levels - Dip Buy Trade
プロフィール
atai Life Sciences is a pharmaceutical company that is developing psychedelics, other hallucinogens, entactogens, and related drugs for treatment of psychiatric conditions. It was founded in 2018 and is headquartered in Berlin, Germany.
The company's pharmaceutical candidates include dimethyltryptamine, -midomafetamine, and ibogaine, as well as EGX-121, 5-MeO-DMT, psilocin, inidascamine, deuterated mitragynine, EGX-A, EGX-B, deuterated etifoxine, and arketamine.
In June 2021, atai became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In January 2023, atai Life Science's leading drug candidate at the time, arketamine, failed to meet its primary endpoint in a clinical trial. Following that, the company laid off 30% of its staff.
Peter Thiel is a major investor in the company. atai Life Sciences has a 22.4% stake in Compass Pathways. Wikipedia
AtaiBeckley Inc について